ANSTO supplies a wide range of nuclear medicines via our licensed facilities.
All our nuclear medicine products are manufactured at ANSTO in Good Manufacturing Practice (GMP) licensed clean rooms. Our facilities are licensed by the Therapeutic Goods Administration. Our adherence to strict quality assurance and control ensures the safety and efficacy of the products.
Mid way through 2019, ANSTO began the manufacture of molybdenum-99 (Mo-99) through a new state-of-the-art nuclear medicine manufacturing facility.
Australia is one of only two countries in the world that has the facilities to complete all the steps required to produce and deliver Mo-99, which then decays to form Tc-99m, to medical practices.
-
Step 1
OPAL reactor
Production of molybdenum-99 (Mo-99), the precursor to technetium-99m (Tc-99m), begins in ANSTO's OPAL reactor.
Learn more -
Step 2
Mo-99 Manufacturing Facility
Following irridation low-enriched uranium target plates are transported to ANSTO’s Mo-99 Manufacturing Facility to separate, purify and extract the Mo-99.
Learn more -
Step 3
Processing and distribution facility
The final steps to prepare Mo-99 take place in our Nuclear medicine processing and distribution facility, also known as Building 23. This facility also assembles, loads, tests and distributes a range of other nuclear medicine products.
View our full list of products -
Step 4
ANSTO's Gentech® Generators
The most widely used radioisotope in nuclear medicine, technetium-99 (Tc-99m), decays from it's parent radioisotope molybdenum-99 within these shielded Gentech® Generators which are manufactured by ANSTO.
Find out more about Tc-99m -
Step 5
Delivering nuclear medicine across Australia
ANSTO delivers thousands of patient doses of Tc-99m to hospitals and nuclear medicine centres in Australian and the region every week.
Ask us a question
If you would like to place a product order or have any further questions please contact the Health team.
Contact
Helpful links
For further information